As tensions might drag over the next decade, investors have to learn to operate under prolonged uncertainty, said Warburg Pincus' Charles Kaye.World Economyread more
Billionaire investor Howard Marks, the co-chairman of Oaktree Capital, predicts there won't be a recession in the U.S. for another two years.US Economyread more
Network officials also said voters should expect more of a Koch focus on grassroots activism throughout the 2020 election cycle.Politicsread more
One person was killed and five others wounded on Thursday in a shooting on the streets of Washington, D.C., not far from the White House, police said.U.S. Newsread more
Stores are extending hours and cities are spending on light shows as China tries to encourage consumers to spend more money at night.China Economyread more
New research suggests fewer girls pursue careers in STEM — science, technology, engineering and math — because they're better than boys at reading.Closing The Gapread more
Stocks in Asia Pacific edged up on Friday as investors digested a series of developments overnight on the U.S.-China trade front that dampened hopes of a deal being reached...Asia Marketsread more
GM's usage of temporary workers, potential closure of plants and health care contributions remain major sticking points, according to people familiar with the talks.Autosread more
In a room full of avowed capitalists, policies that sound to some like socialism are bound not to go over well.Delivering Alpharead more
Trump has criticized Facebook numerous times since becoming president, most recently posting on Twitter that the company's proposed digital currency, libra, will "have little...Technologyread more
Republicans and Democrats have long since separated themselves by ideology, leaving each more uniformly conservative or liberal than ever. And now a new data analysis by the...Politicsread more
In a letter to Gilead CEO John Martin, Healey suggested the costs of the two hepatitis C drugs "may constitute an unfair trade practice in violation of Massachusetts law."
"I write to encourage you to reconsider Gilead's pricing structure for Sovaldi and Harvoni ... so that we may actually see this infectious disease eradicated in the United States in our lifetime," she wrote, adding that her office will "continue to examine this potential claim for unfair commercial conduct."
A full course of Sovaldi currently goes for $84,000, and a 12-week Harvoni treatment costs $94,500.
Healey wrote in her letter date Friday that that if Massachusetts were to purchase Sovaldi at its retail price for all of the people with hepatitis C in the state's prisons, then the costs would "easily exceed" the entire budget for prisoner health care.
After word of the price increases for specialty drugs including Sovaldi, Democratic presidential hopeful Hillary Clinton announced she planned take action against skyrocketing drug costs.
Gilead has said it is committed to expand access to its medicines, regardless of ability to pay. The company has said it offers a "support path" for those who may have trouble paying for its therapies.
"We agree with the Attorney General about the importance of helping all HCV patients — and that the advent of safe, effective regimens means we can now consider the possibility of eradicating the disease," a Gilead spokeswoman told CNBC, adding that the company had reached out to Healey about setting up a meeting to discuss the issue.
"We look forward to working with the Attorney General's office to address questions and concerns and ensure a mutual understanding of the work we are doing to deliver a cure for HCV to as many patients as possible in Massachusetts and around the world," she added.
CNBC obtained a copy of Healey's letter after its contents were reported Wednesday by The Boston Globe.
—CNBC's Meg Tirrell contributed to this report.